Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia

被引：3
|
作者：
Al-Samkari, Hanny [1 ,2 ,9 ]
Jiang, Debbie [3 ,4 ]
Gernsheimer, Terry [3 ,4 ]
Liebman, Howard [5 ]
Lee, Susie [5 ]
Bernheisel, Chelsea
Wojdyla, Matthew [6 ]
Vredenburg, Michael [6 ]
Cuker, Adam [7 ,8 ]
机构：
[1] Massachusetts Gen Hosp, Div Hematol, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Univ Washington, Div Hematol, Seattle, WA USA
[4] Seattle Canc Care Alliance, Seattle, WA USA
[5] Univ Southern Calif, Keck Sch Med, Hematol, Los Angeles, CA USA
[6] Sobi Inc, Durham, NC USA
[7] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA USA
[8] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA USA
[9] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA
来源：
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS | 2023年 / 7卷 / 03期
关键词：
avatrombopag; eltrombopag; immune thrombocytopenia; romiplostim; thrombopoietin receptor;
D O I：
10.1016/j.rpth.2023.100134
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
    Tremblay, Gabriel
    Dolph, Mike
    Bhor, Menaka
    Said, Qayyim
    Roy, Anuja
    Elliott, Brian
    Briggs, Andrew
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2018, 10 : 715 - 721
  • [42] Cost-Effectiveness of Eltrombopag versus Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in England and Wales
    Allen, Rachel
    Bryden, Peter
    Grotzinger, Kelly M.
    Stapelkamp, Ceilidh
    Woods, Bethan
    VALUE IN HEALTH, 2016, 19 (05) : 614 - 622
  • [43] Romiplostim plus danazol as salvage treatment for eltrombopag refractory immune thrombocytopenia: a retrospective pilot study
    Nam, Chang Hyun
    Byun, Ja Min
    Shin, Dong-Yeop
    Hong, Junshik
    Kim, Inho
    Yoon, Sung-Soo
    Koh, Youngil
    BLOOD RESEARCH, 2021, 56 (03) : 202 - 204
  • [44] Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim
    David J. Kuter
    Cynthia Macahilig
    Kelly M. Grotzinger
    Sara A. Poston
    Peter Feng Wang
    Katie L. Dawson
    Melea Ward
    International Journal of Hematology, 2015, 101 : 255 - 263
  • [45] Sequential Use of Romiplostim after Eltrombopag for Refractory Thrombocytopenia in Hydrocarbon-Induced Myelodysplasia
    Morales, Luis F.
    Miyara, Santiago J.
    Guevara, Sara
    Metz, Christine N.
    Shoaib, Muhammad
    Watt, Stacey
    Zafeiropoulos, Stefanos
    McCann-Molmenti, Alexia
    Hayashida, Kei
    Takegawa, Ryosuke
    Shinozaki, Koichiro
    Choudhary, Rishabh C.
    Brindley, Elena C.
    Nishikimi, Mitsuaki
    Kressel, Adam M.
    Alsalmay, Yaser M.
    Mazzotta, Elvio A.
    Cho, Young Min
    Aranalde, Gabriel, I
    Grande, Daniel A.
    Zanos, Stavros
    Becker, Lance B.
    Molmenti, Ernesto P.
    INTERNATIONAL JOURNAL OF ANGIOLOGY, 2021,
  • [46] ECONOMIC EVALUATION OF ROMIPLOSTIM VS ELTROMBOPAG IN THE TREATMENT OF ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA IN MEXICO
    Naranjo, M.
    Alva, M. E.
    Carlos, F.
    VALUE IN HEALTH, 2017, 20 (09) : A893 - A893
  • [47] Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim
    Kuter, David J.
    Macahilig, Cynthia
    Grotzinger, Kelly M.
    Poston, Sara A.
    Wang, Peter Feng
    Dawson, Katie L.
    Ward, Melea
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (03) : 255 - 263
  • [48] Efficacy and Safety Study of Switching from Hetrombopag or Eltrombopag to Avatrombopag in Childhood ITP
    Wei, Hongying
    BLOOD, 2023, 142
  • [49] Durability of Treatment Free Platelet Response in Children with Chronic Immune Thrombocytopenic Purpura Previously Treated with Romiplostim
    Tarantino, Michael D.
    Mistretta, Jessica
    Ansteatt, Kristin T.
    Kreitzer, Sarah
    Barclay, Dominique
    BLOOD, 2024, 144 : 5434 - 5434
  • [50] Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia
    Tremblay, Gabriel
    Dolph, Mike
    Bhor, Menaka
    Said, Qayyim
    Elliott, Brian
    Briggs, Andrew
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2018, 10 : 705 - 713
12345